Drugs / EBVST Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02973113 | Feb 2016 → Sep 2019 | Hodgkins lymphoma, lymphoproliferative syndrome, non-Hodgkin lymphoma, post-transplant lymphoproliferative disease | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBVST Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02973113 ↗ |
| Action | Deplete | “This stimulation trains the EBVSTs to kill cells with EBV proteins on their surface.” NCT02973113 ↗ |
| Modality | Cell therapy | “special immune system cells called EBV-specific cytotoxic T lymphocytes” NCT02973113 ↗ |
| Route | Intravenous | “given by intravenous injection” NCT02973113 ↗ |